Value of Early Circulating Tumor Cells Dynamics to Estimate Docetaxel Benefit in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients

Value of Early Circulating Tumor Cells Dynamics to Estimate Docetaxel Benefit in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients

Circulating tumor cell (CTC) enumeration and changes following treatment have been demonstrated to be superior to PSA response in determining mCRPC outcome in patients receiving AR signaling inhibitors but not taxanes. We carried out a pooled analysis of two prospective studies in mCRPC patients tre...

Full description

Bibliographic Details
Main Authors: Rebeca Lozano, David Lorente, Isabel M. Aragon, Nuria Romero-Laorden, Paz Nombela, Joaquim Mateo, Alison H. M. Reid, Ylenia Cendón, Diletta Bianchini, Casilda Llacer, Shahneen K. Sandhu, Adam Sharp, Pasquale Rescigno, Teresa Garcés, Maria I. Pacheco, Penelope Flohr, Christophe Massard, Pedro P. López-Casas, Elena Castro, Johann S. de Bono, David Olmos
Format: Article
Language:English
Published: MDPI AG 2021-05-01
Series:Cancers
Subjects:
circulating tumor cells
biomarkers
metastatic castration-resistant prostate cancer
docetaxel
PSA
Online Access:https://www.mdpi.com/2072-6694/13/10/2334

Similar Items

Similar Items